Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antipsychotic pharmaceutical composition

A technology of antipsychotic drugs and compositions, applied in the field of medicine, can solve the problems of patients with residual negative symptoms, reduce patient compliance, and poor social function, so as to reduce the incidence of coronary heart disease, reduce medical costs, and reduce type 2 The effect of diabetes incidence

Inactive Publication Date: 2018-12-07
FIRST HOSPITAL OF SHANXI MEDICAL UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] More than 50% of diagnosed SCZ patients have long-term intermittent psychotic symptoms, and most patients have residual negative symptoms, cognitive deficits, poor social function and even mental disability, and their life expectancy is shortened by 10 to 20 years
Dose increases may result in more serious side effects, which in turn may reduce patient compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antipsychotic pharmaceutical composition
  • Antipsychotic pharmaceutical composition
  • Antipsychotic pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] According to the conventional capsule preparation method, olanzapine 12.5g, sertraline hydrochloride 250g, cornstarch 300g, hydroxypropyl cellulose 250g, magnesium oxide 100g, talcum powder 60g, micropowder silica gel 27.5g are mixed and made into granules, with each The filling amount of 200 mg of capsules is packed into capsules, and 5000 capsule preparations are made, and each capsule preparation contains 2.5 mg of olanzapine and 50 mg of sertraline hydrochloride.

Embodiment 2

[0048] Using a conventional preparation method, 10 g of olanzapine, 100 g of sertraline hydrochloride, 50 g of corn starch, 100 g of sodium starch glycolate, 20 g of talcum powder, 10 g of magnesium stearate, and 10 g of microcrystalline cellulose are mixed to make powder, and the The tablet machine compresses the powder to make 2000 tablets, each 150 mg, containing 5 mg of olanzapine and 50 mg of sertraline hydrochloride.

Embodiment 3

[0050] Screen and collect 234 cases of schizophrenia patients meeting the inclusion criteria and exclusion criteria to evaluate the effect of the clinical trial of the pharmaceutical composition of the present invention, and divide the subjects into an experimental group and a control group at random, with 117 cases in each group.

[0051] Inclusion criteria: 1) Meet the diagnostic criteria for schizophrenia in DSM-IV; 2) Educational years ≥ 9 years, right-handed, Han nationality, 3) Age 18-60 years old; 4) Have not received any medical treatment 2 weeks before enrollment 5) half a year ≤ total disease duration ≤ 30 years; 6) PANSS score ≥ 60 points; 7) signed the informed consent.

[0052] Exclusion criteria: 1) Patients who are known to be allergic to olanzapine or any ingredients in the drugs used; 2) Patients with benign prostatic hyperplasia, paralytic ileus and narrow-angle glaucoma; 3) Patients with a history of epilepsy or epilepsy-related diseases; 4) Patients with de...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an antipsychotic pharmaceutical composition which contains active ingredients such as olanzapine and sertraline hydrochloride in a weight ratio of 0.05:1 to 0.2:1. The pharmaceutical composition is applied to treatment of SCZ (Schizophrenia) according to the dosage 5-10mg / d of the olanzapine in the active ingredients. According to the pharmaceutical composition disclosed by the invention, the low-dosage olanzapine and sertraline hydrochloride have an excellent synergistic effect. Compared with medium high-dosage olanzapine for treating the SCZ, the antipsychotic pharmaceutical composition has a considerable effect of eliminating positive symptoms and an excellent effect of eliminating the positive symptoms, affective symptoms and cognitive defects, and is capable of obviously improving the social functions of SCZ patients. Meanwhile, the pharmaceutical composition disclosed by the invention achieves the effects of greatly reducing the fasting blood-glucose andserum lipid levels, preventing significant increase of the body mass index, reducing the incidence of obesity and 2-diabetes mellitus incidence, namely obviously reducing the risk and severity of metabolic syndromes caused by the medium high-dosage olanzapine, and improving the tolerance and compliance of the SCZ patients on the drug.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a pharmaceutical composition, in particular to an antipsychotic pharmaceutical composition, which can effectively treat schizophrenia with a low dose of the pharmaceutical composition of the invention. Background technique [0002] Schizophrenia (SCZ) is a chronic severe mental illness with high recurrence rate, high disability rate, high mortality rate and high disease burden, which is extremely harmful to human health, and its etiology is unknown so far. 1%. [0003] The main symptoms of SCZ include positive symptoms, negative symptoms, affective symptoms and cognitive symptoms. Positive symptoms mainly include hallucinations, delusions, disorganized speech and behavior, nervous or agitated behavior; negative symptoms mainly include emotional bluntness or incoordination, reduced social interaction, withdrawn and withdrawn, lack of speech and interest, decreased willpower, lazy l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/551A61K31/137A61P25/18A61P25/24A61P25/22A61P25/28
CPCA61K31/551A61K31/137A61P25/18A61P25/22A61P25/24A61P25/28A61K2300/00
Inventor 郎小娥薛晓燕李鸿博宋苗侯鑫何潇李建中柴娜闫欣徐勇
Owner FIRST HOSPITAL OF SHANXI MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com